Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6537
    +0.0014 (+0.21%)
     

  • OIL

    83.93
    +0.36 (+0.43%)
     

  • GOLD

    2,360.90
    +18.40 (+0.79%)
     

  • Bitcoin AUD

    98,626.81
    +815.09 (+0.83%)
     

  • CMC Crypto 200

    1,391.32
    -5.21 (-0.37%)
     

  • AUD/EUR

    0.6089
    +0.0016 (+0.26%)
     

  • AUD/NZD

    1.0977
    +0.0019 (+0.18%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,118.12
    +39.26 (+0.49%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,058.48
    +141.20 (+0.79%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th

electroCore, Inc.
·1-min read

ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

Thursday, November 4, 2021, 4:30pm Eastern Time
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13722407
Webcast: electroCore 3Q21 Earnings Webcast

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

CONTACT: Investors: Rich Cockrell CG Capital 404-736-3838 ecor@cg.capital or Media Contact: Jackie Dorsky electroCore 908-313-6331 Jackie.dorsky@electrocore.com